Much research supports the notion that the dementia complex associated with AIDS infection (ADC), is caused by the HIV-1 virus invading the brain macrophages, astrocytes, and microglia triggering various mediators involving contributing cell types setting up a series of cytokine-mediate events leading to the production of toxins which cause neuronal damage. (The HIV-1 envelope protein, glycoprotein 120 (gp120), will set up the same neurotoxic processes.) Many of the cytokine-mediated processes appear to involve signal transduction events which have antioxidant-sensitive steps and cause the induction of various genes, including TGF-alpha and inducible (iNOS). (iNOS mediates the production of large levels of nitric oxide [NO] and either it or one of its metabolites [e.g., peroxynitrite] is toxic to most neurons.) The Principal Investigator and his coworkers have obtained novel and striking preliminary data that may be useful in understanding neuronal damage and offer leads to possibly treat AIDS dementia. They have found, utilizing a direct NO trapping technique in a rat neonate model where gp120 administration causes delayed neuronal development, that high levels of NO are trapped in the brain and that a neuroprotective compound, PBN, not only prevents the NO build-up but prevents the gp120-mediated slowdown in neuronal development. In brain cell culture, gp120 plus various cytokines induce iNOS gene expression and the formation of large amounts of NO. This is prevented by PBN. The long-range goal of the proposed research is to define the role that NO plays in neurological damage, examine the role of escalating cytokine-mediated iNOS gene induction and of oxidative events, and ascertain the neuroprotective mechanism of action of PBN and related compounds in experimental models of ADC. In addition, the results obtained in ADC models will be compared to those obtained from the analysis of CSF of AIDS patients with the view that the knowledge obtained will be valuable in the development of potential therapeutic approaches to the treatment of ADC.
The specific aims are: (1) first, to ascertain the role of NO and oxidative damage and the mediating effect that specific cytokines play in neurotoxicity associate with ADC, utilizing rat brain cell culture and rat neonate models and, second, to ascertain the role of iNOS and the gene expression of specific cytokines in neurotoxic processes using PBN and several related compounds and to ascertain the neuroprotective action of these compounds; (2) to develop a mouse transgenic model wherein gp120 expression in astrocytes can be turned """"""""on"""""""" or """"""""off"""""""" at any specific time in the animal's life and conduct studies to ascertain the role that iNOS and specific cytokine gene expression plays in neurologic damage; and (3) to ascertain whether NO oxidation products (NO2-, NO3-), as well as oxidized protein and specific cytokines, are altered in the CSF of AIDS patients in reference to their degree of dementia and their staging in terms of disease progression.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
3R01NS035747-03S1
Application #
2848874
Study Section
AIDS and Related Research Study Section 7 (ARRG)
Program Officer
Kerza-Kwiatecki, a P
Project Start
1996-08-01
Project End
2001-04-30
Budget Start
1998-05-01
Budget End
1999-04-30
Support Year
3
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Oklahoma Medical Research Foundation
Department
Type
DUNS #
937727907
City
Oklahoma City
State
OK
Country
United States
Zip Code
73104
Floyd, Robert A; Towner, Rheal A; He, Ting et al. (2011) Translational research involving oxidative stress and diseases of aging. Free Radic Biol Med 51:931-41
Floyd, Robert A (2009) Serendipitous findings while researching oxygen free radicals. Free Radic Biol Med 46:1004-13
Hensley, Kenneth; Benaksas, Elaine J; Bolli, Roberto et al. (2004) New perspectives on vitamin E: gamma-tocopherol and carboxyelthylhydroxychroman metabolites in biology and medicine. Free Radic Biol Med 36:1-15
Maples, Kirk R; Green, A Richard; Floyd, Robert A (2004) Nitrone-related therapeutics: potential of NXY-059 for the treatment of acute ischaemic stroke. CNS Drugs 18:1071-84
Williamson, Kelly S; Gabbita, S Prasad; Mou, Shenyun et al. (2002) The nitration product 5-nitro-gamma-tocopherol is increased in the Alzheimer brain. Nitric Oxide 6:221-7
Floyd, Robert A; Hensley, Kenneth; Forster, Michael J et al. (2002) Nitrones, their value as therapeutics and probes to understand aging. Mech Ageing Dev 123:1021-31
Hensley, Kenneth; Floyd, Robert A (2002) Reactive oxygen species and protein oxidation in aging: a look back, a look ahead. Arch Biochem Biophys 397:377-83
Floyd, Robert A; Hensley, Kenneth (2002) Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases. Neurobiol Aging 23:795-807
Floyd, R A; West, M; Hensley, K (2001) Oxidative biochemical markers; clues to understanding aging in long-lived species. Exp Gerontol 36:619-40
Salsman, S; Felts, N; Pye, Q N et al. (2001) Induction of Akt phosphorylation in rat primary astrocytes by H2O2 occurs upstream of phosphatidylinositol 3-kinase: no evidence for oxidative inhibition of PTEN. Arch Biochem Biophys 386:275-80

Showing the most recent 10 out of 25 publications